Twente study: The real-world endeavor resolute versus xience V drug-eluting stent study in twente: Study design, rationale and objectives

Netherlands Heart Journal

Volumn 18, Issue 7, 2010, Pages 360-364

  Basalus, M W Z ^a   Tandjung, K ^a   van Houwelingen, K G ^a   Stoel, M G ^a   de Man, F H A F ^a   Louwerenburg, J W ^a   Said S A M ^b   Linssen, G C M ^c   Kleijne, M A W J ^d   Van der Palen, J ^e   Huisman, J ^a   Verhorst, P M J ^a   von Birgelen, C ^e  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b Hospital Group Twente   (Netherlands)

^c Hospital Group Twente   (Netherlands)

^d University of Twente ^*  (Netherlands)

^e UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Angioplasty; Coronary artery diseases; Drug eluting stents; Percutaneous coronary; Randomized controlled trial; Thrombosis; Transluminal

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS; GLYCERYL TRINITRATE; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HEPARIN; ZOTAROLIMUS;

ARTICLE; BARE METAL STENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; ENDEAVOR RESOLUTE DRUG ELUTING STENT; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; XIENCE V DRUG ELUTING STENT;

EID: 77957672262     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03091792     Document Type: Article

References (30)

1. Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schomig A. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J. 2006;27:260-6.
2. Vermeersch P, Agostoni P, Verheye S, Van den HP, Convens C, Bruining N, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol. 2006;48:2423-31.
3. Briguori C, Colombo A, Airoldi F, Focaccio A, Iakovou I, Chieffo A, et al. Sirolimus-eluting stent implantation in diabetic patients with multivessel coronary artery disease. Am Heart J. 2005;150:807-13.
4. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937-48.
5. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119:3198-206.
6. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519-21.
7. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667-78.
8. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008;299:1903-13.
9. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation. 2009;119:680-6.
10. Tsuchida K, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher AM, et al. One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial). Euro Intervention. 2005;1:266-72.
11. Meredith IT, Worthley S, Whitbourn R, Walters DL, McClean D, Horrigan M. et al. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv. 2009;2:977-85.
12. Meredith IT, Worthley S, Whitbourn R, Walters D, Popma J, Cutlip D, et al. The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial. Euro Intervention. 2007;3:50-3.
13. Basalus MW, Ankone MJ, van Houwelingen GK, de Man FH, von Birgelen C. Coating irregularities of durable polymer-based drug-eluting stents as assessed by scanning electron microscopy. Euro Intervention. 2009;5:157-65.
14. Basalus MW, von Birgelen C. Bench side testing of drug-eluting stent surface and geometry. J Interv Cardiol. 2010;2:159-75.
15. Hezi-Yamit A, Sullivan C, Wong J, David L, Chen M, Cheng P, et al. Novel high-throughput polymer biocompatibility screening designed for SAR (structure-activity relationship): application for evaluating polymer coatings for cardiovascular drug-eluting stents. Comb Chem High Throughput Screen. 2009;12:664-76.
16. Udipi K, Melder RJ, Chen M, Cheng P, Hezi-Yamit A, Sullivan C, et al. The next generation Endeavor Resolute Stent: role of the Bio Linx Polymer System. Euro Intervention. 2007;3:137-9.
17. Carter AJ, Brodeur A, Collingwood R, Ross S, Gibson L, Wang CA, et al. Experimental efficacy of an everolimus eluting cobalt chromium stent. Cathet Cardiovasc Interv. 2006;68:97-103.
18. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333-42.
19. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008;299:1903-13.
20. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-51.
21. Vranckx P, Cutlip DE, Mehran R, Kint PP, Silber S, Windecker S, et al. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. Euro Intervention. 2010;5:871-4.
22. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2001;37:1478-92.
23. Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, et al. Comparison of zotarolimuseluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006;48:2440-7.
24. Popma JJ, Mauri L, O'Shaughnessy C, Overlie P, McLaurin B, Almonacid A, et al. Frequency and clinical consequences associated with sidebranch occlusion during stent implantation using zotarolimus-eluting and paclitaxel-eluting coronary stents. Circ Cardiovasc Interv. 2009;2:133-9.
25. Mukherjee D, Moliterno DJ. Second-generation drug-eluting stents and the continuous need for rapidly available real-world data. JACC Cardiovasc Interv. 2009;2:1236-9.
26. Fajadet J, Morice MC, Bode C, Barragan P, Serruys PW, Wijns W, et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation. 2005;111:1040-4.
27. Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med. 2009;360:1946-59.
28. Galloe AM, Thuesen L, Kelbaek H, Thayssen P, Rasmussen K, Hansen PR, et al. Comparison of paclitaxel- and sirolimuseluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA. 2008;299:409-16.
29. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375:201-9
30. Silber S. A new and rapid scoring system to assess the scientific evidence from clinical trials. J Interv Cardiol. 2006;19:485-92.